請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85286
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 姜至剛(Chih-Kang Chiang) | |
dc.contributor.author | Jia-Huang Chen | en |
dc.contributor.author | 陳佳煌 | zh_TW |
dc.date.accessioned | 2023-03-19T22:55:14Z | - |
dc.date.copyright | 2022-10-03 | |
dc.date.issued | 2022 | |
dc.date.submitted | 2022-07-29 | |
dc.identifier.citation | 1. Johansen, K.L., et al., US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis, 2021. 77(4 Suppl 1): p. A7-A8. 2. National Health Insurance Annual Report 2021- 2022. National Health Insurance Administration, Ministry of Health and Welfare, 2022. 3. Doyle, J.F. and L.G. Forni, Acute kidney injury: short-term and long-term effects. Critical Care, 2016. 20(1): p. 188. 4. Coca, S.G., et al., Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis, 2009. 53(6): p. 961-73. 5. Bedford, M., et al., Acute kidney injury and CKD: chicken or egg? 2012. 59(4): p. 485-91. 6. Chawla, L.S., et al., Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol, 2017. 13(4): p. 241-257. 7. Saran, R., et al., US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis, 2016. 67(3 Suppl 1): p. Svii, S1-305. 8. James, M.T., et al., A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis, 2015. 66(4): p. 602-12. 9. Zoccali, C., et al., The systemic nature of CKD. Nat Rev Nephrol, 2017. 13(6): p. 344-358. 10. Chen, J.H. and C.K. Chiang, Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence. Toxins (Basel), 2021. 14(1): p. 8. 11. Bahloul, M., et al., Incidence and prognosis of acute renal failure in the intensive care unit. Retrospective study of 216 cases. 2003. 81(4): p. 250-257. 12. Carbonell, N., et al., Acute renal failure in critically ill patients. A prospective epidemiological study. Nefrologia., 2004. 24(1): p. 47-53. 13. Requião-Moura, L.R., et al., Ischemia and reperfusion injury in renal transplantation: hemodynamic and immunological paradigms. Einstein (Sao Paulo), 2015. 13(1): p. 129-35. 14. Sutton, T.A., C.J. Fisher, and B.A.J.K.i. Molitoris, Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int, 2002. 62(5): p. 1539-49. 15. Romanov, V., et al., Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidney. Kidney Int, 1997. 52(1): p. 93-102. 16. Bonventre, J.V. and A.J.K.i. Zuk, Ischemic acute renal failure: an inflammatory disease? Kidney Int, 2004. 66(2): p. 480-485. 17. Schena, F.P.J.K.i.S., Role of growth factors in acute renal failure. Kidney Int Suppl, 1998. 66: p. S11-5. 18. Basile, D.P., M.D. Anderson, and T.A. Sutton, Pathophysiology of acute kidney injury. Compr Physiol, 2012. 2(2): p. 1303-53. 19. Hsu, R.K. and C.Y. Hsu, The Role of Acute Kidney Injury in Chronic Kidney Disease. Semin Nephrol, 2016. 36(4): p. 283-92. 20. Grande, M.T., et al., Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med, 2015. 21(9): p. 989-97. 21. Yang, L., et al., Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med, 2010. 16(5): p. 535-543. 22. Lovisa, S., et al., Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med, 2015. 21(9): p. 998-1009. 23. Wu, C.F., et al., Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol, 2013. 182(1): p. 118-31. 24. Humphreys, B.D., et al., Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol, 2010. 176(1): p. 85-97. 25. Vanholder, R., et al., Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int, 2003. 63(5): p. 1934-43. 26. Vanholder, R., et al., A bench to bedside view of uremic toxins. J Am Soc Nephrol, 2008. 19(5): p. 863-70. 27. Gowda, S., et al., Markers of renal function tests. N Am J Med Sci, 2010. 2(4): p. 170-3. 28. Chmielewski, M., et al., The peptidic middle molecules: is molecular weight doing the trick? Semin Nephrol, 2014. 34(2): p. 118-34. 29. Wikoff, W.R., et al., Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A, 2009. 106(10): p. 3698-703. 30. Niwa, T., Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr, 2010. 20(5 Suppl): p. S2-6. 31. Deltombe, O., et al., Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Toxins (Basel), 2015. 7(10): p. 3933-46. 32. Jheng, J.R., et al., The double-edged sword of endoplasmic reticulum stress in uremic sarcopenia through myogenesis perturbation. J Cachexia Sarcopenia Muscle, 2018. 9(3): p. 570-84. 33. Hung, S.C., et al., Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. Kidney Int, 2016. 89(3): p. 574-85. 34. Vanholder, R., et al., The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol, 2014. 25(9): p. 1897-907. 35. Wu, I.W., et al., p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant, 2011. 26(3): p. 938-47. 36. Opdebeeck, B., et al., Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. J Am Soc Nephrol, 2019. 30(5): p. 751-766. 37. Jourde-Chiche, N. and S. Burtey, Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. Kidney Int, 2020. 97(6): p. 1102-1104. 38. Bao, Y.W., et al., Kidney disease models: tools to identify mechanisms and potential therapeutic targets. Zool Res, 2018. 39(2): p. 72-86. 39. Yang, L., et al., Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nature Medicine, 2010. 16(5): p. 535-543. 40. Le Clef, N., et al., Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. PLoS One, 2016. 11(3): p. e0152153. 41. Wei, J., et al., New mouse model of chronic kidney disease transitioned from ischemic acute kidney injury. Am J Physiol Renal Physiol, 2019. 317(2): p. F286-F295. 42. Wei, Q., et al., Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS One, 2014. 9(9): p. e106647. 43. Matsuzaki, T., et al., Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute [corrected] renal failure. Kidney Int, 2007. 71(6): p. 539-47. 44. Roth, M., A. Obaidat, and B. Hagenbuch, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol, 2012. 165(5): p. 1260-87. 45. Delanaye, P., E. Cavalier, and H. Pottel, Serum Creatinine: Not So Simple! Nephron, 2017. 136(4): p. 302-308. 46. Frank, H., et al., Effect of short-term high-protein compared with normal-protein diets on renal hemodynamics and associated variables in healthy young men. Am J Clin Nutr, 2009. 90(6): p. 1509-16. 47. Branten, A.J., G. Vervoort, and J.F. Wetzels, Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant, 2005. 20(4): p. 707-11. 48. Wu, V.C., et al., In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis, 2013. 16(3): p. 609-24. 49. Lee, S.A., et al., Distant Organ Dysfunction in Acute Kidney Injury: A Review. Am J Kidney Dis, 2018. 72(6): p. 846-856. 50. Kellum, J.A., et al., Acute kidney injury. Nat Rev Dis Primers, 2021. 7(1): p. 52. 51. Shen, W.C., et al., Indoxyl sulfate enhances IL-1β-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFκB/AP-1 pathway. Arch Toxicol, 2016. 90(11): p. 2779-2792. 52. Yadav, E., et al., Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications. Respir Med, 2020. 174: p. 106193. 53. Yabuuchi, N., et al., Indoxyl Sulfate as a Mediator Involved in Dysregulation of Pulmonary Aquaporin-5 in Acute Lung Injury Caused by Acute Kidney Injury. Int J Mol Sci, 2016. 18(1). 54. Yamaguchi, J., T. Tanaka, and R. Inagi, Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy? Nephron, 2017. 135(3): p. 201-206. 55. Asai, M., S. Kumakura, and M. Kikuchi, Review of the efficacy of AST-120 (KREMEZIN(®)) on renal function in chronic kidney disease patients. Ren Fail, 2019. 41(1): p. 47-56. 56. Cha, R.H., et al., Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract, 2017. 36(1): p. 68-78. 57. Schulman, G., et al., Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol, 2015. 26(7): p. 1732-46. 58. Kechagia, M., et al., Health benefits of probiotics: a review. ISRN Nutr, 2013. 2013: p. 481651. 59. Meijers, B.K., et al., p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant, 2010. 25(1): p. 219-24. 60. Taki, K., F. Takayama, and T. Niwa, Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr, 2005. 15(1): p. 77-80. 61. Nakabayashi, I., et al., Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant, 2011. 26(3): p. 1094-8. 62. Lee, T.H., et al., Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis. Int J Mol Med, 2020. 45(4): p. 1130-1140. 63. Sirich, T.L., et al., Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. Kidney Int, 2017. 91(5): p. 1186-1192. 64. Madero, M., et al., Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor. Clin J Am Soc Nephrol, 2019. 14(3): p. 394-402. 65. Kragh-Hansen, U., Molecular aspects of ligand binding to serum albumin. Pharmacol Rev, 1981. 33(1): p. 17-53. 66. Tao, X., et al., Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study. Sci Rep, 2016. 6: p. 23389. 67. Zhou, L., Z. Zuo, and M.S. Chow, Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol, 2005. 45(12): p. 1345-59. 68. Li, J., et al., Improved dialysis removal of protein-bound uremic toxins by salvianolic acids. Phytomedicine, 2019. 57: p. 166-173. 69. Ron David, W.P., Signal integration in the endoplasmic reticulum unfolded protein response. Nature reviews Molecular cell biology, 2007. 8(7): p. 519-529. 70. Wang Miao, R.J.K., The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nature Reviews Cancer, 2014. 14(9): p. 581-97. 71. Anne Bertolotti, et al., Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature cell biology, 2000. 2(6): p. 326-332. 72. Walter, P. and D. Ron, The unfolded protein response: from stress pathway to homeostatic regulation. Science, 2011. 334(6059): p. 1081-6. 73. Ronald C. Wek and Douglas R. Cavener, Translational control and the unfolded protein response. Antioxidants redox signaling, 2007. 9(12): p. 2357-2372. 74. Vattem, K.M. and R.C. Wek, Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A, 2004. 101(31): p. 11269-74. 75. Ma, Y., et al., Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol, 2002. 318(5): p. 1351-65. 76. Karen D. McCullough, et al., Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Molecular cellular biology, 2001. 21(4): p. 1249-59. 77. Marciniak, S.J., et al., CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev, 2004. 18(24): p. 3066-077. 78. Liu, C.Y., M. Schroder, and R.J. Kaufman, Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem, 2000. 275(32): p. 24881-5. 79. Han, D., et al., IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell, 2009. 138(3): p. 562-75. 80. Yoshida, H., et al., XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell, 2001. 107(7): p. 881-91. 81. Yoshida, H., et al., A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell, 2003. 4(2): p. 265-71. 82. Wakabayashi, S. and H. Yoshida, The essential biology of the endoplasmic reticulum stress response for structural and computational biologists. Comput Struct Biotechnol J, 2013. 6: p. e201303010. 83. Urano, F., et al., Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science, 2000. 287(5453): p. 664-6. 84. Hollien, J. and J.S. Weissman, Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science, 2006. 313(5783): p. 104-7. 85. Tam, A.B., A.C. Koong, and M. Niwa, Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. Cell Rep, 2014. 9(3): p. 850-8. 86. Hong, M., et al., Endoplasmic reticulum stress triggers an acute proteasome-dependent degradation of ATF6. J Cell Biochem, 2004. 92(4): p. 723-32. 87. Shen, J. and R. Prywes, Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6. J Biol Chem, 2004. 279(41): p. 43046-51. 88. Lee, K., et al., IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev, 2002. 16(4): p. 452-66. 89. Okada, T., et al., Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J, 2002. 366(Pt 2): p. 585-94. 90. Yamamoto, K., et al., Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell, 2007. 13(3): p. 365-76. 91. Galindo, I., et al., The ATF6 branch of unfolded protein response and apoptosis are activated to promote African swine fever virus infection. Cell Death Dis, 2012. 3: p. e341. 92. Lee, A.H., N.N. Iwakoshi, and L.H. Glimcher, XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol, 2003. 23(21): p. 7448-459. 93. Moore, P.C., et al., Parallel Signaling through IRE1α and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res, 2019. 79(24): p. 6190-203. 94. Duwaerts, C.C., et al., Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1α. Cell Death Differ, 2021. 28(5): p. 1455-1465. 95. Liu, X.H., et al., Ischemic postconditioning protects myocardium from ischemia/reperfusion injury through attenuating endoplasmic reticulum stress. Shock, 2008. 30(4): p. 422-7. 96. Shu, S., et al., Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease. EBioMedicine, 2018. 37: p. 269-280. 97. Chiang, C.K., et al., Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med, 2011. 17(11-12): p. 1295-305. 98. Wang, Y., et al., Intermedin protects against renal ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress. BMC Nephrol, 2015. 16: p. 169. 99. Jao, T.M., et al., ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int, 2019. 95(3): p. 577-89. 100. Pawlak, M., P. Lefebvre, and B. Staels, Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol, 2015. 62(3): p. 720-33. 101. Kaushal, G.P., K. Chandrashekar, and L.A. Juncos, Molecular Interactions Between Reactive Oxygen Species and Autophagy in Kidney Disease. Int J Mol Sci, 2019. 20(15). 102. Koritzinsky, M., et al., Two phases of disulfide bond formation have differing requirements for oxygen. J Cell Biol, 2013. 203(4): p. 615-27. 103. Pajares, M., A. Cuadrado, and A.I. Rojo, Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol, 2017. 11: p. 543-53. 104. Chen, J., Z. Zhang, and L. Cai, Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes Metab J, 2014. 38(5): p. 337-45. 105. Jin, J.K., et al., ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart. Circ Res, 2017. 120(5): p. 862-75. 106. Cullinan, S.B., et al., Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol, 2003. 23(20): p. 7198-209. 107. Cullinan, S.B. and J.A. Diehl, Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol, 2006. 38(3): p. 317-32. 108. Hassan, H., et al., Essential Role of X-Box Binding Protein-1 during Endoplasmic Reticulum Stress in Podocytes. J Am Soc Nephrol, 2016. 27(4): p. 1055-65. 109. Fedeles, S.V., et al., Sec63 and Xbp1 regulate IRE1α activity and polycystic disease severity. J Clin Invest, 2015. 125(5): p. 1955-67. 110. Ishikawa, Y., et al., Spliced XBP1 Rescues Renal Interstitial Inflammation Due to Loss of Sec63 in Collecting Ducts. J Am Soc Nephrol, 2019. 30(3): p. 443-59. 111. Ferrè, S., et al., Renal tubular cell spliced X-box binding protein 1 (Xbp1s) has a unique role in sepsis-induced acute kidney injury and inflammation. Kidney Int, 2019. 96(6): p. 1359-1373. 112. Fan, Y., et al., Inhibition of Reticulon-1A–Mediated Endoplasmic Reticulum Stress in Early AKI Attenuates Renal Fibrosis Development. J Am Soc Nephrol, 2017. 28(7): p. 2007-021. 113. Wu, C.-H., Role of XBP1 in acute kidney injury to chronic kidney disease transition, in Graduate Institute of Toxicology. 2016, National Taiwan University: Taipei. p. 90. 114. Ferenbach, D.A. and J.V. Bonventre, Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol, 2015. 11(5): p. 264-76. 115. Puchtler, H. and H. Isler, The effect of phosphomolybdic acid on the stainability of connective tissues by various dyes. J Histochem Cytochem, 1958. 6(4): p. 265-70. 116. Inagi, R., Y. Ishimoto, and M. Nangaku, Proteostasis in endoplasmic reticulum--new mechanisms in kidney disease. Nat Rev Nephrol, 2014. 10(7): p. 369-78. 117. Kawakami, T., et al., Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol, 2010. 299(3): p. F568-76. 118. Niwa, T. and H. Shimizu, Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr, 2012. 22(1): p. 102-6. 119. Sun, C.Y., S.C. Chang, and M.S. Wu, Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int, 2012. 81(7): p. 640-50. 120. Xu, J., L. Zhou, and Y. Liu, Cellular Senescence in Kidney Fibrosis: Pathologic Significance and Therapeutic Strategies. Front Pharmacol, 2020. 11: p. 601325. 121. Dou, L., et al., The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int, 2004. 65(2): p. 442-51. 122. Kim, S.H., et al., Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest, 2012. 92(4): p. 488-98. 123. Mah, L.J., A. El-Osta, and T.C. Karagiannis, gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia, 2010. 24(4): p. 679-86. 124. Hoste, E.A.J., et al., Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol, 2018. 14(10): p. 607-625. 125. Slocum, J.L., M. Heung, and S. Pennathur, Marking renal injury: can we move beyond serum creatinine? Transl Res, 2012. 159(4): p. 277-89. 126. Gocze, I., et al., Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study. Ann Surg, 2018. 267(6): p. 1013-1020. 127. Roager, H.M. and T.R. Licht, Microbial tryptophan catabolites in health and disease. Nat Commun, 2018. 9(1): p. 3294. 128. Devlin, A.S., et al., Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe, 2016. 20(6): p. 709-715. 129. Wang, Y., et al., Targeting the gut microbial metabolic pathway with small molecules decreases uremic toxin production. Gut Microbes, 2020. 12(1): p. 1-19. 130. Black, A.P., et al., Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients? J Ren Nutr, 2018. 28(3): p. 208-14. 131. Liu, S.-H., et al., Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro. Oncotarget, 2016. 7(16): p. 22116. 132. Luo, C., et al., Wnt9a Promotes Renal Fibrosis by Accelerating Cellular Senescence in Tubular Epithelial Cells. J Am Soc Nephrol, 2018. 29(4): p. 1238-56. 133. Jin, H., et al., Epithelial innate immunity mediates tubular cell senescence after kidney injury. JCI Insight, 2019. 4(2): e125490. 134. Andrade, L., et al., Acute Kidney Injury as a Condition of Renal Senescence. Cell Transplant, 2018. 27(5): p. 739-753. 135. Adijiang, A., et al., Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr, 2011. 21(1): p. 105-9. 136. Humphreys, B.D., et al., Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest, 2013. 123(9): p. 4023-35. 137. Kishi, S., et al., Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses. J Clin Invest, 2019. 129(11): p. 4797-4816. 138. Chen, J.H., et al., Early elimination of uremic toxin ameliorates AKI-to-CKD transition. Clin Sci (Lond), 2021. 135(23): p. 2643-2658. 139. Joshi, A., et al., The mitochondrial HSP90 paralog TRAP1 forms an OXPHOS-regulated tetramer and is involved in mitochondrial metabolic homeostasis. BMC Biol, 2020. 18(1): p. 10. 140. Sisinni, L., et al., TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. J Pathol, 2017. 243(1): p. 123-134. 141. Chen, J.F., et al., TRAP1 ameliorates renal tubulointerstitial fibrosis in mice with unilateral ureteral obstruction by protecting renal tubular epithelial cell mitochondria. FASEB J, 2017. 31(10): p. 4503-4514. 142. Ishani, A., et al., Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol, 2009. 20(1): p. 223-8. 143. Chevalier, R.L., The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol, 2016. 311(1): p. F145-61. 144. Cybulsky, A.V., Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases. Nat Rev Nephrol, 2017. 13(11): p. 681-96. 145. Inagi, R., et al., Preconditioning with endoplasmic reticulum stress ameliorates mesangioproliferative glomerulonephritis. J Am Soc Nephrol, 2008. 19(5): p. 915-22. 146. Zager, R.A., A.C. Johnson, and K. Becker, Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and 'end-stage' kidney disease. Am J Physiol Renal Physiol, 2011. 301(6): p. F1334-45. 147. Arai, S., et al., Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med, 2016. 22(2): p. 183-93. 148. Madhusudhan, T., et al., Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy. Nat Commun, 2015. 6: p. 6496. 149. Fedeles, S.V., et al., Sec63 and Xbp1 regulate IRE1alpha activity and polycystic disease severity. J Clin Invest, 2015. 125(5): p. 1955-67. 150. Kaser, A., et al., XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell, 2008. 134(5): p. 743-56. 151. Fang, P., et al., IRE1α-XBP1 signaling pathway regulates IL-6 expression and promotes progression of hepatocellular carcinoma. Oncol Lett, 2018. 16(4): p. 4729-36. 152. Chen, C. and X. Zhang, IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling. J Transl Med, 2017. 15(1): p. 42. 153. Zeng, L., et al., Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. Proc Natl Acad Sci U S A, 2009. 106(20): p. 8326-31. 154. Grandjean, J.M.D., et al., Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol, 2020. 16(10): p. 1052-1061. 155. Madhavan, A., et al., Pharmacologic IRE1/XBP1s activation promotes systemic adaptive remodeling in obesity. Nat Commun, 2022. 13(1): p. 608. 156. Dufey, E., et al., Genotoxic stress triggers the activation of IRE1α-dependent RNA decay to modulate the DNA damage response. Nat Commun, 2020. 11(1): p. 2401. 157. Duan, Q., et al., MicroRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo. J Transl Med, 2015. 13: p. 363. 158. Duan, Q., et al., MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis. J Cell Physiol, 2015. 230(8): p. 1964-73. 159. Denby, L., et al., MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol, 2014. 25(1): p. 65-80. 160. Lee, A.H., et al., Dual and opposing roles of the unfolded protein response regulated by IRE1alpha and XBP1 in proinsulin processing and insulin secretion. Proc Natl Acad Sci U S A, 2011. 108(21): p. 8885-90. 161. Blazanin, N., et al., ER stress and distinct outputs of the IRE1alpha RNase control proliferation and senescence in response to oncogenic Ras. Proc Natl Acad Sci U S A, 2017. 114(37): p. 9900-9905. 162. Grynberg, K., F.Y. Ma, and D.J. Nikolic-Paterson, The JNK Signaling Pathway in Renal Fibrosis. Front Physiol, 2017. 8: p. 829. 163. Zhang, J., et al., Downregulation of XBP1 protects kidney against ischemia-reperfusion injury via suppressing HRD1-mediated NRF2 ubiquitylation. Cell Death Discov, 2021. 7(1): p. 44. 164. Zhang, X., et al., Knockdown of TRAP1 promotes cisplatin-induced apoptosis by promoting the ROS-dependent mitochondrial dysfunction in lung cancer cells. Mol Cell Biochem, 2020. 476(2): p. 1075-1082. 165. Palladino, G., et al., TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. Endocr Relat Cancer, 2016. 23(9): p. 699-709. 166. Condelli, V., et al., TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. Cancer Res, 2014. 74(22): p. 6693-704. 167. Miled, C., C. Mann, and G. Faye, Xbp1-mediated repression of CLB gene expression contributes to the modifications of yeast cell morphology and cell cycle seen during nitrogen-limited growth. Mol Cell Biol, 2001. 21(11): p. 3714-24. 168. Thorpe, J.A. and S.R. Schwarze, IRE1alpha controls cyclin A1 expression and promotes cell proliferation through XBP-1. Cell Stress Chaperones, 2010. 15(5): p. 497-508. 169. Tao, R., et al., Xbp1-mediated histone H4 deacetylation contributes to DNA double-strand break repair in yeast. Cell Res, 2011. 21(11): p. 1619-33. 170. Wang, N., et al., Knockdown of XBP1 by RNAi in Mouse Granulosa Cells Promotes Apoptosis, Inhibits Cell Cycle, and Decreases Estradiol Synthesis. Int J Mol Sci, 2017. 18(6): p. 1152. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85286 | - |
dc.description.abstract | 慢性腎臟病(Chronic kidney disease, CKD)為多重器官衰竭之惡化因子,臨床上不僅引起健康危害,於醫療保健支出所造成的經濟負擔同樣為全球關注的議題。因此找尋潛在致病因子及治療策略仍然是臨床上的當務之急。急性腎損傷(Acute kidney injury, AKI)為慢性腎臟病進展的長期風險因子以及急性腎損傷後異常修復為造成慢性腎臟病轉變的觀念於近年來逐漸受到重視。然而,急性腎損傷後導致的異常修復的因子眾多且尚未研究透徹。硫酸吲哚酚(Indoxyl sulfate, IS)為一種親蛋白性尿毒素,過去研究指出其在CKD患者體內濃度與腎臟纖維化成正相關。此外,未折疊蛋白反應(unfolded protein response, UPR)活化與腎損傷進展有所關聯。團隊先前研究發現XBP1s (Spliced X box binding protein 1),一種適應性調控轉錄因子,蛋白質表現量伴隨腎臟纖維化進展而逐漸下降。然而,IS是否引起急性腎損傷後的異常修復以及XBP1s在AKI至CKD轉變過程中的角色尚未完全釐清。因此,本研究將探討IS於AKI後的作用機轉以及XBP1s參與在AKI至CKD轉變過程中的角色。 首先,我們以C57BL6小鼠利用單側腎損傷再灌流建立AKI to CKD模型,發現隨著腎纖維化進展,血清中IS濃度逐漸增加並且伴隨有機陽離子通道蛋白(organic anion transporter 1, OAT1)表現降低,然而小分子尿毒素則未有顯著上升情形。進一步探討IS於AKI to CKD過程中作用,小鼠於早期腎損傷後第五天餵食IS前驅物(Indole)及AST-120 (親蛋白性尿毒素吸附劑)並於損傷後第十天將對側腎臟切除以加速尿毒素累積,而第十五天進行犧牲。結果顯示餵食indole組別顯著增加小鼠血清中IS濃度並加劇腎臟纖維化、衰老相關旁泌生長因子基因表現及內質網壓力蛋白恆定失調,而合併給予AST-120組別則能緩解IS累積所誘導腎損傷惡化情形。進一步探討IS暴露加速腎損傷作用機轉,利用人類腎小管上皮細胞HK-2暴露於IS合併培養於厭氧袋中以模擬缺氧再灌流(Hypoxia/reperfusion, H/R)損傷。結果顯示IS處理能夠加劇H/R引起之細胞週期G2/M停滯、上皮間質轉換(Epithelial-mesenchymal transition, EMT)與內質網壓力;透過合併給予化學伴護因子(4-phenylbutyric acid, 4-PBA)減緩內質網壓力能夠改善IS加劇H/R所誘導之EMT及細胞週期G2/M停滯作用,說明IS累積於AKI後介導內質網壓力恆定失調導致CKD進展扮演重要角色。另一方面,為證實AKI 至CKD進展過程中XBP1蛋白表現降低為腎纖維化進展之致病因子,本研究建立近端腎小管上皮細胞XBP1條件性敲除轉殖鼠(XBP1 conditional knockout mice, XBP1cKO)並以UIRI誘導之。結果顯示XBP1cKO相較基因型對照組以UIRI誘導後能夠引起更顯著之腎臟纖維化、腎損傷、細胞週期G2/M停滯、DNA損傷及發炎相關mRNA表現,說明XBP1喪失為腎損傷後導致腎功能失衡之重要因素。進一步探討可能受XBP1s影響之下游標的,HK-2細胞以基因減量技術降低XBP1表現並進行蛋白質體學分析。結果顯示腫瘤壞死因子受體相關蛋白1 (TNF receptor-associated protein 1, Trap1)表現下降最為顯著,並且經由in vitro驗證XBP1s能夠轉錄調控Trap1表現,此外,本研究也以UIRI、單側輸尿管結紮(Unilateral ureteral obstruction, UUO)及腺嘌呤誘導腎病變模式證實Trap1伴隨XBP1s表現逐漸下降。最後我們以大量表現Trap1發現能夠回復腎小管細胞因XBP1缺失所引起之細胞週期G2/M停滯及促纖維生長因子分泌。 總結以上,本研究探討兩種造成AKI後加速進展至CKD之風險因子:IS累積與XBP1s缺失。AKI早期移除親蛋白性尿毒素IS能夠作為延緩患者進展至CKD之有效治療策略;以及XBP1s缺失於腎損傷後扮演促纖維化作用,透過活化腎小管細胞partial-EMT及旁泌與自泌作用加速腎纖維化進展,此外本研究也證實XBP1s-Trap1能夠作為恆定AKI後腎臟纖維化進展之新穎訊號途徑。未來也將持續探索XBP1s所調控之下游標的以及評估選擇性活化XBP1s作為治療AKI to CKD之潛力。 | zh_TW |
dc.description.abstract | Chronic kidney disease (CKD) development is one of the deterioration factors for multiorgan failure which not only raises public health issues but also imposes socioeconomic burden worldwide. Exploring the potential pathogenetic factors and therapeutic strategies are still emerging unmet medical needs. Acute kidney injury (AKI) is a long-term risk for CKD development and the concept of maladaptive repair after AKI contributes to CKD transition has been extensively emphasized. Nevertheless, aberrant kidney recovery after AKI is multifactorial and still poorly understood. The accumulation of indoxyl sulfate (IS), a protein-bound uremic toxin, has been identified as a threat for the progression of renal fibrosis. Besides, the activation of the unfolded protein response (UPR) is also closely linked to the pathophysiology of renal injuries. Our previous study revealed that XBP1s, a crucial regulator of adaptive UPR, was downregulated and associated with renal fibrosis progression. However, the underlying mechanisms regarding IS caused aberrant kidney recovery after AKI and loss of XBP1s during AKI to CKD transition are still unknown. Therefore, we aim to investigate the effects of IS on tubular damage and the involvement of XBP1s in the pathophysiology of AKI to CKD transition in this study. First of all, we established AKI to CKD model in C57BL6 mice utilizing unilateral ischemia-reperfusion injury (UIRI), which revealed that IS accumulation without the synergetic small molecule uremic toxins increased and that renal fibrosis development is associated with serum IS accumulation. To evaluate the impact of IS on AKI to CKD transition, we administered indole or AST-120, a precursor of IS and an oral spherical carbonaceous adsorbent respectively, on the early stage of UIRI (day 5). Then, a contralateral nephrectomy (Nx) was performed on day 10 to accelerate uremic toxins accumulation and animals were sacrificed on day 15. Our results demonstrated IS potentiated renal fibrosis, senescence-associated secretory phenotype (SASP), and impaired endoplasmic reticulum (ER) homeostasis, which can be ameliorated by concomitant AST-120 administration. To further investigate the underlying mechanism, human proximal tubular epithelial cells were exposed to IS and an anaerobic bag to mimic hypoxia-reperfusion (H/R) insults. The results showed that IS exposure potentiated H/R induced cell cycle G2/M arrest, epithelial-mesenchymal transition (EMT), and aggravated ER stress activation. The ER chemical chaperon, 4-phenylbutyric acid (4-PBA), successfully reversed the IS potentiated maladaptive repair process, suggesting that IS accumulation plays an important role in proteostasis imbalance during AKI to CKD progression. On the other hand, the loss of XBP1s expression was found during AKI to CKD transition and negatively correlated with renal fibrosis development. Therefore, we further investigate the role of XBP1s in UIRI model using proximal tubular XBP1 conditional knockout (XBP1cKO) transgenic mice. XBP1cKO mice exhibited more severe renal fibrosis, cell cycle arrest in G2/M phase, and DNA damage in UIRI model than wide-type littermates. To figure out the potential downstream effector protein regulated by XBP1s, proteomic analysis was performed in HK-2 cells silenced of XBP1. Proteomic analysis identified that TNF receptor-associated protein 1 (Trap1) was a potential downstream target transcriptionally regulated by XBP1s. We also examined that the downregulation of XBP1s coincided with decreased Trap1 protein expression in UIRI, unilateral ureteral obstruction (UUO), adenine induced nephropathy model. Trap1 overexpression can alleviate silencing XBP1 induced profibrotic factor expressions and cell cycle arrest. In summary, we identified the potential risk factors that contribute to advanced CKD development after AKI insults including IS accumulation and the loss of XBP1s in tubular epithelial cells. Timely IS elimination in the early stage of AKI is likely to be an effective strategy in the prevention and treatment of the AKI to CKD transition. In addition, we also confirmed the loss of XBP1 in kidney injury was profibrotic, and the process was mediated by autocrine and paracrine regulations in combination. We also identified the XBP1-Trap1 axis as an instrumental mechanism responsible for post-AKI fibrosis, which is a novel regulatory pathway. The more potential regulatory effectors of XBP1s are still needed to be explored and the therapeutic approach through selective XBP1s activation during AKI to CKD to be determined in future studies. | en |
dc.description.provenance | Made available in DSpace on 2023-03-19T22:55:14Z (GMT). No. of bitstreams: 1 U0001-2807202215572600.pdf: 8301671 bytes, checksum: 4b4c5222d853ff6345499bd77829135e (MD5) Previous issue date: 2022 | en |
dc.description.tableofcontents | 口試委員審定書 I 誌謝 II 中文摘要 IV ABSTRACT VI CONTENTS XI Chapter 1 Introduction 1 1.1 The Updated ADQI Consensus for AKI to CKD continuum 1 1.2 Pathophysiology change of acute kidney injury 3 1.3 Maladaptive repair from AKI leading to CKD progression 4 1.4 Etiology and Pathophysiological Roles of Uremic Toxin 5 1.5 The retention of IS in kidney disease models 6 1.6 Diagnostic value of IS in disease progression 7 1.7 Strategies for removing indoxyl sulfate 8 1.7.1 The spherical carbon adsorbent 8 1.7.2 Probiotic Supplements 9 1.7.3 Albumin Binding Displacer 9 1.8 Fundamental Roles of Endoplasmic Reticulum Stress and Unfolded Protein Responses 10 1.8.1 PERK- eIF2α-ATF4 axis 11 1.8.2 IRE1α-XBP1 axis 11 1.8.3 ATF6 signaling 12 1.9 Disturbance of UPR implicated in kidney injury 13 1.10 Current evidence for XBP1s involvement in renal disease 14 Chapter 2 Aims 17 2.1 Rationale 17 2.2 Hypothesis 17 2.3 Specific aims 17 Chapter 3 Materials and Methods 19 3.1 Cell culture 19 3.2 Experimental animals and animal models 19 3.2.1 Unilateral ischemia-reperfusion injury model 20 3.2.2 UIRI with contralateral nephrectomy (UNx) model 20 3.2.3 Unilateral ureteral obstruction (UUO) 21 3.2.4 Adenine induced nephropathy model 21 3.3 Histological analysis 21 3.4 RNA extraction, reverse transcription, RT-PCR, and quantitative PCR 22 3.5 Intracellular reactive oxygen species detection 22 3.6 Cell cycle analysis 22 3.7 Serum indoxyl sulfate measurement 23 3.8 Immunohistochemistry staining 23 3.9 Immunofluorescence staining 24 3.10 TUNEL assay 24 3.11 MTS assay 25 3.12 Plasmid construction and cell transfection 25 3.13 Cell trans-differentiation assay 25 3.14 Protein identification by LC-MS/MS analysis 26 3.15 Luciferase reporter assay 26 3.16 Chromatin immunoprecipitation (ChIP) assays 26 3.17 Statistical analysis 27 Chapter 4 Results and Discussions 28 4.1 Early elimination of uremic toxin ameliorates AKI-to-CKD transition 28 4.1.1 Results 28 4.1.1.1 Establish a mouse model of AKI to CKD transition by UIRI surgery 28 4.1.1.2 Renal fibrosis development in the UIRI model 28 4.1.1.3 UIRI induced tubular epithelial cells arrest in cell cycle G2/M phase 28 4.1.1.4 Protein-bound uremic toxin Indoxyl Sulfate (IS) accumulation without small molecule uremic toxins increased in the UIRI model 29 4.1.1.5 AST-120 administration attenuated renal fibrosis in two-stage UIRI with contralateral nephrectomy 29 4.1.1.6 IS accumulation is associated with renal fibrosis development 30 4.1.1.7 AST-120 treatment modulated UPRs and SASP in AKI-to-CKD transition 30 4.1.1.8 The mechanisms of IS administration in hypoxia-reperfusion injury in vitro 31 4.1.1.9 4-PBA, an ER chemical chaperon, reversed IS-potentiated cell cycle arrest and EMT in vitro 32 4.1.2 Discussion 33 4.2 The down-regulation of XBP1, an unfolded protein response effector, promotes acute kidney injury to chronic kidney disease transition 38 4.2.1 Results 38 4.2.1.1 XBP1 decrease in renal fibrosis model 38 4.2.1.2 XBP1 knockout in renal proximal tubules leads to more severe kidney IRI 38 4.2.1.3 XBP1 specific deletion in proximal tubular aggravates maladaptive repair process 39 4.2.1.4 Loss of XBP1 leads to cell cycle G2/M arrest 40 4.2.1.5 The profibrotic paracrine effect of XBP1 silenced HK2 cells 40 4.2.1.6 Trap1, a cell cycle-regulated protein, is identified as downregulated in XBP1 deficiency model 41 4.2.1.7 Spliced XBP1 transcriptionally regulates Trap1 expression 42 4.2.1.8 Trap1 overexpression rescues silenced XBP1 induced G2/M arrest 43 4.2.2 Discussion 44 Chapter 5 Conclusion and Future Perspective 50 Figures 51 Tables 98 References 101 Appendix 112 | |
dc.language.iso | en | |
dc.title | 內質網壓力於急性腎損傷至慢性腎臟病轉換:專注於早期硫酸吲哚酚移除與XBP1s作用 | zh_TW |
dc.title | Endoplasmic Reticulum Stress Implicated in AKI to CKD Transition: Focus on Early Elimination of Indoxyl Sulfate and Impact of XBP1s Signaling | en |
dc.type | Thesis | |
dc.date.schoolyear | 110-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 劉興華(Shing-Hwa Liu),楊榮森(Rong-Sen Yang),許美鈴(Meei-Ling Sheu),洪冠予(Kuan-Yu Hung) | |
dc.subject.keyword | 急性腎損傷至慢性腎臟病轉換,未折疊蛋白反應,硫酸吲哚酚,AST-120,剪切型X-box 結合蛋白,腫瘤壞死因子受器相關蛋白1, | zh_TW |
dc.subject.keyword | AKI to CKD transition,unfolded protein response,indoxyl sulfate,AST-120,XBP1s,Trap1, | en |
dc.relation.page | 112 | |
dc.identifier.doi | 10.6342/NTU202201837 | |
dc.rights.note | 同意授權(限校園內公開) | |
dc.date.accepted | 2022-07-29 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
dc.date.embargo-lift | 2022-10-03 | - |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2807202215572600.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 8.11 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。